Inactive

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to competitively procure, through full and open competition, a contracto... The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to competitively procure, through full and open competition, a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI). The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations. As respiratory syncytial virus (RSV) vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations. Vaccine effectiveness estimates will include effectiveness against emerging variants of concern and duration of protection. These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation. Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV and influenza. The requirement includes three timed phases: 1) Phase I – Participating Healthcare Facilities and Protocols (requiring the Contractor to identify and receive CDC-approval for the required number and diversity of technically qualified healthcare facilities to comprise the surveillance network; update CDC-approved case-control protocol to measure vaccine effectiveness in adults and expand to include RSV surveillance; and submit and obtain IRB approval or exemption to conduct the research activities based upon the proposed protocols). 2) Phase II – Enrollment and Data Collection (requiring the Contractor (and through the Contractor, the healthcare facilities) to enroll patients who meet the case definition as cases/controls for VE evaluation or surveillance; collect and test upper respiratory specimens by PCR, and provide weekly enrollment updates; collect data on enrolled cases/controls using updated and CDC-approved data collection forms; review patient medical records and conduct patient interviews for the data collection form; collect additional biospecimens on enrolled cases/controls; and maintain a protected database, provide data management, and synthesize and clean the data for analysis). 3) Phase III – Project Artifacts (requiring the Contractor to provide a final, complete dataset to CDC and to write with CDC manuscripts for publication). The contractor must comply with all policies and procedures (i.e., CDC and medical industry) related to human subjects, patient care, and the collection of information containing patient medical histories and other personally identifiable information (PII). The period of performance is base period from 1 September 2022 through 31 August 2023, followed by 2 1-year option periods. The Government will release the solicitation, including any subsequent amendments, on the SAM.gov website. The Government anticipates the solicitation will be available approximately 15 days from the date of this notice, with an anticipated closing date/proposal due date of 30 days from the date of release of the solicitation. No telephone or written requests for the solicitation will be accepted. After solicitation release, vendors should regularly access the website to access any updates. The Government is not obligated to and will not pay for any information received from potential sources as a result of this pre-solicitation notice. There are no responses due based on this pre-solicitation notice. Questions or comments regarding this notice may be addressed to Mark Draluck at syq1@cdc.gov.